AFT Pharmaceuticals (ASX:AFP) has announced a new partnership with one of its research and development partners, Belgium’s Hyloris Pharmaceuticals, to develop a novel locally acting product for treating burning mouth syndrome (BMS).
Under the terms of the agreement, AFT and Hyloris will co-invest in the development of HY-090 for registration, approval and commercialisation.
Under the terms of the agreement, Hyloris will be accountable for the execution and coordination of formulation and related activities. AFT will manage clinical trials and oversee all aspects to ensure effective planning, execution, and monitoring throughout the trial lifecycle.
For product commercialisation strategies, Hyloris will be responsible for Europe, jointly responsible with AFT for the US. AFT will be responsible for all other territories.
AFT managing director Dr Hartley Atkinson said, “This collaboration brings together the strengths of AFT and Hyloris, combining strong internal R&D capabilities and solid expertise in clinical trial management building on our current Maxigesic IV partnership. I look forward to the success and growth it will bring to our companies and importantly assists our international expansion goals."
“We had previously flagged to the market at our half year reporting that we were targeting increasing our R&D pipeline with two projects under diligence. This was one of those projects but we confirm that we are still working to complete diligence on a further three projects. We see that further R&D projects are important to drive our long-term global expansion,” said Dr Atkinson.
BMS is characterised by burning pain in a normal-appearing oral mucosa lasting at least four to six months.